ESMO 2021: DESTINY-Lung01 Highlights Promise of Trastuzumab Deruxtecan in Relapsed/Refractory Advanced HER2-Mutated Non-Small Cell Lung Cancer
Findings support trastuzumab deruxtecan as new standard treatment in the second-line or beyond setting
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.